YDC105 / YD Global, SapiensBio - LARVOL DELTA

Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer. (PubMed, J Natl Cancer Inst) - "Externally-validated primary breast cancer genetic susceptibility predictors are relevant for SBC risk prediction and should be prioritized for risk stratification in survivors."

Journal • Breast Cancer • Oncology • Solid Tumor

YD Life Science-Sapiens Bio, Preclinical Success of Idiopathic Pulmonary Fibrosis Treatment (Unicorn Factory) - "YD Life Science and Sapiens Bio announced on the 28th that they have successfully completed the preclinical trial of their jointly developed idiopathic pulmonary fibrosis (IPF) treatment candidate (YDC105/SBC101)....In particular, in the 90-day repeated-administration toxicity test on rats and beagles, which is a key preclinical test, all test animals completed the test safely without any deaths or clinical abnormalities, confirming the safety of the candidate....'We expect that the technology transfer that the company is conducting will also gain momentum as the candidate has obtained the results necessary for entering clinical trials.'"

Preclinical • Idiopathic Pulmonary Fibrosis